Assessing the Knowledge, Attitude, and Practice of Healthcare Workers on the Herpes Zoster Vaccine in Saudi Arabia: A Cross-Sectional Study
Cureus,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 11, 2025
Herpes
zoster
(HZ),
known
as
shingles
disease,
has
several
complications
that
greatly
affect
elderly
and
immunocompromised
people.
Despite
evidence
for
HZ
vaccine
efficiency
cost-effectiveness,
the
uptake
of
is
lower
than
other
common
adult
vaccines.
Strong
recommendations
by
healthcare
workers
(HCWs)
could
increase
uptake.
This
study
aimed
to
investigate
HCWs'
knowledge,
attitude,
practice
recombinant
(RZV)
in
Saudi
Arabia
identify
gaps
barriers
recommendation.
A
cross-sectional,
questionnaire-based
was
conducted
different
hospitals
Riyadh,
Arabia,
between
December
2023
March
2024.
An
electronic
self-administered
validated
questionnaire
assesses
HCWs
regarding
sent
all
hospital
staff.
The
collected
data
were
organized,
entered
on
an
Excel
sheet,
statistically
analyzed
using
SPSS
software.
Pearson's
chi-square
test
Monte
Carlo
exact
tests
used
analysis.
total
309
responded
survey.
Family
physicians,
infectious
diseases
doctors,
dermatologists
are
essential
recommend
vaccines
Arabia.
In
particular,
264
(86.4%)
correctly
identified
doses
RZV.
However,
148
(47.9%)
incorrectly
believed
side
effects
from
first
dose
a
valid
reason
not
receive
second
dose.
Most
(n
=
235,
76.1)
agreed
they
need
more
direction
which
patients
eligible
RZV
vaccine.
physicians
patient
groups
mentioned
Advisory
Committee
Immunization
Practices
(ACIP)
recommendations.
85
(27.5%)
recommended
healthy
adults
aged
18-49
years.
Ninety-nine
(32%)
declined
did
think
at
risk
developing
73
(23.6%)
due
fears
immediate
effects.
Among
strategies
distributing
pamphlets
having
hotline
or
website
available
discuss
vaccination,
255
(82.5%)
235
(76.1%)
HCWs,
respectively.
Physicians
generally
knowledgeable
about
but
guidance
ACIP
reactions
dose,
limited
availability,
perception
been
adequately
studied
among
Pamphlets
discussion
Язык: Английский
Sex, Age, and Previous Herpes Zoster Infection Role on Adverse Events Following Immunization with Adjuvanted Recombinant Vaccine
Pathogens,
Год журнала:
2025,
Номер
14(2), С. 195 - 195
Опубликована: Фев. 15, 2025
Adverse
events
following
immunizations
(AEFIs)
with
recombinant
zoster
vaccine
(RZV)
are
underexplored
in
fragile
populations.
This
study
aims
to
assess
incidence,
duration,
and
characteristics
of
AEFIs,
focusing
on
the
impact
sex,
age,
prior
Herpes
Zoster
(HZ)
infection
a
frail
population,
including
solid
organ
transplant
recipients.
We
conducted
an
observational
patients
receiving
RZV,
AEFIs
were
classified
as
local
or
systemic
analyzed
for
patterns
across
groups.
showed
that
females
had
higher
incidence
(p
=
0.02),
both
symptoms,
such
swelling
+/-
redness
at
site
injection
fatigue,
after
first
second
doses.
Younger
adults
experienced
more
reactions,
while
older
reported
(e.g.,
swelling,
p
0.01).
Moreover,
previous
HZ
exhibited
dose
(68%
vs.
38%,
0.001).
In
conclusion,
clinical
history
significantly
influenced
AEFI
manifestations.
Therefore,
it
is
important
personalize
vaccination
strategies
populations,
by
tailored
administration
monitoring
plans,
especially
individuals
infection,
improve
safety
patient
outcomes.
Язык: Английский
Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report
Human Vaccines & Immunotherapeutics,
Год журнала:
2025,
Номер
21(1)
Опубликована: Апрель 20, 2025
Epidermolysis
bullosa
is
a
rare
genetic
disorder
characterized
by
skin
fragility
and
blistering,
resulting
from
mutations
in
dermal-epidermal
junction
structural
proteins.
Disease
severity
varies,
with
some
cases
involving
extensive
damage
complications
secondary
to
chronic
inflammation.
Patients
immune-mediated
dermatological
conditions
face
heightened
risk
of
Herpes
Zoster
Post-Herpetic
Neuralgia,
particularly
during
immunosuppressive
treatments.
A
10-year-old
female
Recessive
Dystrophic
Bullosa
received
off-label
Recombinant
adjuvanted
Vaccine
(RZV)
-
approved
individuals
18
years
age
older
before
initiating
Janus
kinase
inhibitor
therapy,
required
manage
the
underlying
condition.
Two
standard
RZV
doses
were
administered
on
February
22
April
29,
2024.
No
immediate
vital
sign
alterations
nor
Adverse
Events
Following
Immunization
documented
first
7
days
after
immunization.
6-month
follow-up
revealed
no
relevant
emergent
clinical
events
episodes.
In
conclusion,
case
offers
preliminary
insights
into
safety
for
high-risk
pediatric
patients.
However,
robust
efficacy
studies
are
warranted
support
implementation
vulnerable
under
age.
Язык: Английский
Herpes Zoster Vaccination: Insights into Efficacy, Safety, and Guidelines
Vaccines,
Год журнала:
2025,
Номер
13(5), С. 477 - 477
Опубликована: Апрель 28, 2025
Background:
The
varicella–zoster
virus
(VZV)
is
a
human
herpesvirus
that
primarily
causes
varicella
(chickenpox)
as
an
initial
infection,
characterized
by
distinctive
skin
lesions.
It
can
later
reactivate,
leading
to
herpes
zoster
(shingles).
Once
reactivated,
VZV
infection
may
result
in
serious
complications,
the
most
common
being
postherpetic
neuralgia.
Fortunately,
vaccination
prevent
this
condition.
Objectives:
In
study,
we
provide
comprehensive
analysis
of
vaccines,
including
clinical
trials,
safety
profiles,
and
reimbursement
guidelines
across
various
countries.
Results:
Our
findings
confirm
vaccine’s
effectiveness
diverse
populations,
aligning
with
previous
trials
real-world
data,
summarize
global
guidelines.
Язык: Английский
Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study
Vaccines,
Год журнала:
2024,
Номер
12(9), С. 990 - 990
Опубликована: Авг. 29, 2024
Background:
Vaccination
is
the
most
effective
strategy
for
preventing
infectious
diseases
and
related
complications,
proving
its
efficacy
crucial
success
adherence,
especially
newly
introduced
vaccines,
such
as
adjuvanted
recombinant
herpes
zoster
virus
vaccination
(RZV).
In
this
observational
real-life
study,
we
recorded
adverse
effects
following
immunization
(AEFIs)
after
RZV
administration
in
frail
populations.
Methods:
A
total
of
271
subjects
underwent
at
Center,
University
Hospital
“San
Giovanni
di
Dio
e
Ruggi
d’Aragona”,
Salerno,
Italy.
Most
were
solid
organ
transplant
recipients
(kidney,
77.1%;
liver,
4.8%).
Demographics,
clinical
data,
AEFIs
(type,
duration,
medications
used)
recorded.
Results:
Overall,
37%
participants
reported
least
one
AEFI
first
dose,
predominantly
pain
injection
site
(60%),
while
41%
did
so
second
dose
(pain
62%
cases).
Medications
more
frequently
used
treatment
(28%)
rather
than
(13%)
(p
=
0.01).
After
stratification
by
sex,
females
experienced
males,
particularly
local
skin
reactions.
Conclusions:
Our
study
added
evidence
safety
tolerability
adults.
Язык: Английский
Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review
Vaccine X,
Год журнала:
2024,
Номер
20, С. 100544 - 100544
Опубликована: Авг. 3, 2024
The
Herpes
Zoster
(HZ)
poses
a
significant
public
health
threat,
leading
to
morbidity
and
occasional
mortality
in
unvaccinated
adults
aged
50
older.
With
over
95
%
of
individuals
this
age
group
globally
having
prior
exposure
Varicella-Zoster
Virus,
substantial
portion
the
world's
population
is
susceptible
developing
HZ.
Without
vaccination,
reaching
85
years
face
lifetime
risk
Organizational
logistical
barriers
further
hinder
vaccination
efforts,
involving
complexities
cost
management,
demanding
vaccine
storage
requirements,
supply
limitations,
distribution
challenges,
absence
streamlined
status
collection
system,
healthcare
system
deficiencies.
Язык: Английский
Post-Marketing Surveillance of Adverse Events for the Recombinant Zoster Vaccine Among the Population over 50 Years Old in Hangzhou, China
Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1376 - 1376
Опубликована: Дек. 6, 2024
Objectives:
This
study
aimed
to
evaluate
the
safety
profile
of
recombinant
zoster
vaccine
(RZV)
after
its
marketing
in
China.
Methods:
We
present
a
descriptive
analysis
and
signal
assessment
adverse
events
following
immunization
(AEFI)
associated
with
RZV
between
September
2020
December
2023.
The
data
collected
includes
demographic
characteristics
classification
AEFI
cases,
while
was
evaluated
using
reporting
odds
ratio
(ROR).
Results:
In
total,
we
documented
275
cases
vaccination,
rate
76.22/10,000
doses
administered.
Notably,
only
one
case
classified
as
serious,
rates
were
significantly
higher
among
females,
individuals
aged
50–59
years,
those
residing
rural
areas.
Furthermore,
for
first
dose
exceeded
that
second
dose.
Among
reported
98.91%
attributed
product-related
reactions,
97.45%
initially
by
either
recipient
or
their
guardians.
interval
vaccination
symptom
onset
predominant
within
3
d
vaccination.
disproportionality
identified
five
positive
signals—fever
(37.5–38.5
°C),
injection
site
reactions
greater
than
5
cm,
pain,
Henoch
Schönlein
purpura
(HSP),
swelling—which
suggests
stronger
association
expected
threshold.
Conclusion:
summary,
demonstrated
favorable
profile.
However,
continued
monitoring
research
on
long-term
implications
are
needed.
Язык: Английский